A simple yet accurate model could help streamline ROP screening
Regulators step in to stop stem cell clinics from marketing unproven therapies.
Introducing the easy-to-use system that offers patients lower risks of complications – regardless of surgeon experience
Researchers identified the cell types associated with schizophrenia mutations
With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease?
Could artificial intelligence help repurpose old drugs for suffers of the degenerative disorder?
What if, instead of waiting for a donor cornea to become available, you could just print one?
Peter T. Kissinger
Why we need more chemistry in the clinic if we’re to reach the goal of individualized medicine.
New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.
The promise of genome editing is tempered for genetically heterogeneous diseases – introducing a new approach for rhodopsin-dependent retinitis pigmentosa.
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.